Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.
OBJECTIVE--To compare the efficacy and side effects of 400 mg, 800 mg, and 1200 mg zidovudine daily in patients with AIDS or advanced HIV infection. DESIGN--Randomised, double blind, parallel group multicentre study. SETTING--Hospital departments of infectious diseases and dermatology in Denmark, Sw...
Published in: | BMJ |
---|---|
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group Ltd
1992
|
Subjects: | |
Online Access: | http://www.bmj.com/cgi/content/short/304/6818/13 https://doi.org/10.1136/bmj.304.6818.13 |
id |
fthighwire:oai:open-archive.highwire.org:bmj:304/6818/13 |
---|---|
record_format |
openpolar |
spelling |
fthighwire:oai:open-archive.highwire.org:bmj:304/6818/13 2023-05-15T16:52:01+02:00 Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. 1992-01-04 00:00:00.0 text/html http://www.bmj.com/cgi/content/short/304/6818/13 https://doi.org/10.1136/bmj.304.6818.13 en eng BMJ Publishing Group Ltd http://www.bmj.com/cgi/content/short/304/6818/13 http://dx.doi.org/10.1136/bmj.304.6818.13 Copyright (C) 1992, BMJ Publishing Group Ltd RESEARCH ARTICLE TEXT 1992 fthighwire https://doi.org/10.1136/bmj.304.6818.13 2013-05-27T05:12:59Z OBJECTIVE--To compare the efficacy and side effects of 400 mg, 800 mg, and 1200 mg zidovudine daily in patients with AIDS or advanced HIV infection. DESIGN--Randomised, double blind, parallel group multicentre study. SETTING--Hospital departments of infectious diseases and dermatology in Denmark, Sweden, Norway, Finland, and Iceland. SUBJECTS--474 patients: 126 (27%) with AIDS; 248 (52%) with HIV related symptoms; 100 (21%) with low CD4+ cell counts. INTERVENTIONS--Zidovudine 400 mg (160 patients), 800 mg (158), or 1200 mg (156) daily. All patients received one capsule from each of three bottles four times daily. MAIN OUTCOME MEASURES--Survival; incidence of new HIV related events; CD4+ cell count; quality of life; incidence of haematological side effects. RESULTS--460 (97%) of the 474 patients had not received zidovudine previously. The median follow up period was 19 months, during which the death rates in the three treatment groups were 23% (36/160 patients), 23% (36/158), and 19% (30/156) respectively (p = 0.49; log rank test). One year after the trial was terminated the death rates were 38% (61/160), 41% (64/158), and 44% (68/156) respectively (p = 0.54). There was no significant difference between the groups in time to a new AIDS defining event or death, average number of events per patient, decline in CD4+ cell counts, wellbeing (visual analogue scale), or Karnofsky score. Zidovudine was withdrawn in 132 (28%) patients, mainly because of side effects (71 cases; 15%). The incidences of anaemia and leucopenia, time to first dose reduction, and numbers of patients withdrawn were all dose related. CONCLUSION--Zidovudine should be limited to 400-600 mg daily in patients with AIDS or advanced HIV infection. Text Iceland HighWire Press (Stanford University) Norway BMJ 304 6818 13 17 |
institution |
Open Polar |
collection |
HighWire Press (Stanford University) |
op_collection_id |
fthighwire |
language |
English |
topic |
RESEARCH ARTICLE |
spellingShingle |
RESEARCH ARTICLE Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
topic_facet |
RESEARCH ARTICLE |
description |
OBJECTIVE--To compare the efficacy and side effects of 400 mg, 800 mg, and 1200 mg zidovudine daily in patients with AIDS or advanced HIV infection. DESIGN--Randomised, double blind, parallel group multicentre study. SETTING--Hospital departments of infectious diseases and dermatology in Denmark, Sweden, Norway, Finland, and Iceland. SUBJECTS--474 patients: 126 (27%) with AIDS; 248 (52%) with HIV related symptoms; 100 (21%) with low CD4+ cell counts. INTERVENTIONS--Zidovudine 400 mg (160 patients), 800 mg (158), or 1200 mg (156) daily. All patients received one capsule from each of three bottles four times daily. MAIN OUTCOME MEASURES--Survival; incidence of new HIV related events; CD4+ cell count; quality of life; incidence of haematological side effects. RESULTS--460 (97%) of the 474 patients had not received zidovudine previously. The median follow up period was 19 months, during which the death rates in the three treatment groups were 23% (36/160 patients), 23% (36/158), and 19% (30/156) respectively (p = 0.49; log rank test). One year after the trial was terminated the death rates were 38% (61/160), 41% (64/158), and 44% (68/156) respectively (p = 0.54). There was no significant difference between the groups in time to a new AIDS defining event or death, average number of events per patient, decline in CD4+ cell counts, wellbeing (visual analogue scale), or Karnofsky score. Zidovudine was withdrawn in 132 (28%) patients, mainly because of side effects (71 cases; 15%). The incidences of anaemia and leucopenia, time to first dose reduction, and numbers of patients withdrawn were all dose related. CONCLUSION--Zidovudine should be limited to 400-600 mg daily in patients with AIDS or advanced HIV infection. |
format |
Text |
title |
Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
title_short |
Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
title_full |
Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
title_fullStr |
Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
title_full_unstemmed |
Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. |
title_sort |
double blind dose-response study of zidovudine in aids and advanced hiv infection. nordic medical research councils' hiv therapy group. |
publisher |
BMJ Publishing Group Ltd |
publishDate |
1992 |
url |
http://www.bmj.com/cgi/content/short/304/6818/13 https://doi.org/10.1136/bmj.304.6818.13 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://www.bmj.com/cgi/content/short/304/6818/13 http://dx.doi.org/10.1136/bmj.304.6818.13 |
op_rights |
Copyright (C) 1992, BMJ Publishing Group Ltd |
op_doi |
https://doi.org/10.1136/bmj.304.6818.13 |
container_title |
BMJ |
container_volume |
304 |
container_issue |
6818 |
container_start_page |
13 |
op_container_end_page |
17 |
_version_ |
1766042146684534784 |